Q1 EPS Estimates for Zimmer Biomet Raised by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities researchers at Zacks Research upped their Q1 2026 earnings per share (EPS) estimates for shares of Zimmer Biomet in a research report issued on Thursday, April 3rd. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.12 per share for the quarter, up from their prior forecast of $2.11. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet’s FY2026 earnings at $8.80 EPS and Q1 2027 earnings at $2.25 EPS.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the business earned $2.20 earnings per share.

ZBH has been the subject of a number of other research reports. Barclays lowered their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. JMP Securities reissued a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Royal Bank of Canada cut their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Finally, Truist Financial restated a “hold” rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Price Performance

Shares of ZBH opened at $107.46 on Monday. The company has a 50 day moving average of $107.32 and a two-hundred day moving average of $107.23. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet has a twelve month low of $97.69 and a twelve month high of $129.50. The company has a market cap of $21.39 billion, a price-to-earnings ratio of 24.15, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ZBH. Dunhill Financial LLC increased its holdings in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares in the last quarter. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $25,000. Menard Financial Group LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth about $30,000. Accredited Wealth Management LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth about $36,000. Finally, Kentucky Trust Co purchased a new position in Zimmer Biomet in the 4th quarter valued at about $39,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.70% of the stock is currently owned by insiders.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.